NEW THERAPIES IN UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMORS

Ana Georgiana Berescu; Andreea Mihaela Stoica; Alexandra Bolocan

doi:10.33695/jss.v1i3.189

Ana Georgiana Berescu The University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania
Andreea Mihaela Stoica University of Medicine and Pharmacy "Carol Davila" Bucharest, Romania
Alexandra Bolocan The University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania; General Surgery and Emergency Clinic III – The University Emergency Hospital of Bucharest, Romania

DOI: https://doi.org/10.33695/jss.v1i3.189

Keywords: pancreatic neuroendocrine tumors, chemotherapy, sunitinib, everolimus

Abstract

Until recently, the main form of treatment for the pancreatic neuroendocrine tumors was the surgical resection (the Whipple operation). Due to technological advances, which resulted in more frequent diagnosis, attempts were made to discover other less radical forms of treatment, including limited surgical resection and multiple forms of chemotherapy. Surgical resection has shown benefit only on small lesions with no metastases. According to the recent studies chemotherapeutic agents have shown substantial benefits in terms of survival and disease progression, especially sunitinib and everolimus.